Genomtec S.A., a biotech company that develops solutions for molecular diagnostics, including the innovative Genomtec ID diagnostic system, put all 730 thousand shares of the J-series offered at a maximum price of 11 PLN per share as part of the first public offering.
It is noted that investors have noticed a tremendous potential and innovation of the Genomtec ID mobile diagnostic genetic platform, which has been reflected in the huge investors’ interest. The overall declaration for the intended shares purchase has been achieved for the amount exceeding 50 million PLN. The funding will secure industrialization process and also global commercialization of the Genomtec ID platform. Company’s goal is to debut on the NewConnect Stock Exchange market at GPW in Q1 2021.
Find out more at the article in the following link.